Estrogens, Cancer and Immunity
Open Access
Abstract
Sex hormones are included in many physiological and pathological pathways. Estrogens belong to steroid hormones active in female sex. Estradiol (E2) is the strongest female sex hormone and, with its receptors, contributes to oncogenesis, cancer progression and response to treatment. In recent years, a role of immunosurveillance and suppression of immune response in malignancy has been well defined, forming the basis for cancer immunotherapy. The interplay of sex hormones with cancer immunity, as well as the response to immune checkpoint inhibitors, is of interest. In this review, we investigate the impact of sex hormones on natural immune response with respect to main active elements in anticancer immune surveillance: dendritic cells, macrophages, lymphocytes and checkpoint molecules. We describe the main sex-dependent tumors and the contribution of estrogen in their progression, response to treatment and especially modulation of anticancer immune response.Keywords
This publication has 151 references indexed in Scilit:
- Expression levels of estrogen receptor beta in conjunction with aromatase predict survival in non-small cell lung cancerLung Cancer, 2011
- Cellular senescence: putting the paradoxes in perspectiveCurrent Opinion in Genetics & Development, 2011
- Combined Analysis of Estrogen Receptor β-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor OutcomeClinical Cancer Research, 2011
- Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and womenCarcinogenesis, 2010
- PD-1, gender, and autoimmunityAutoimmunity Reviews, 2010
- Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal WomenJournal of Clinical Oncology, 2010
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trialThe Lancet, 2009
- Aromatase Expression Predicts Survival in Women with Early-Stage Non–Small Cell Lung CancerCancer Research, 2007
- Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort studyBreast Cancer Research and Treatment, 2007
- Breast cancer and hormone-replacement therapy in the Million Women StudyThe Lancet, 2003